Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A 52-week, Multicenter, Randomized, Double-blind Study of Subcutaneous Secukinumab to Demonstrate Efficacy as Assessed by Psoriasis Area and Severity Index at 16 Weeks of Treatment Compared to Ustekinumab and to Assess Long-term Safety, Tolerability and Efficacy in Subjects With Moderate to Severe Plaque Psoriasis (CLEAR)

Next Previous
X
Search
Trial Profile

A 52-week, Multicenter, Randomized, Double-blind Study of Subcutaneous Secukinumab to Demonstrate Efficacy as Assessed by Psoriasis Area and Severity Index at 16 Weeks of Treatment Compared to Ustekinumab and to Assess Long-term Safety, Tolerability and Efficacy in Subjects With Moderate to Severe Plaque Psoriasis (CLEAR)

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 09 Nov 2022

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Secukinumab (Primary) ; Ustekinumab
  • Indications Plaque psoriasis
  • Focus Therapeutic Use
  • Acronyms CLEAR
  • Sponsors Novartis; Novartis Pharmaceuticals

    • Most Recent Events

    • 05 Nov 2022 Results of a pooled analysis from two clinical trials: CLEAR and CLARITY trials assessing level of response in lower limbs versus other body regions in patient with moderate to severe psoriasis published in the BioDrugs
    • 25 Apr 2021 Results of a pooled analysis from two clinical studies: CLEAR and CLARITY presented at the American Academy of Dermatology Virtual Meeting Experience 2021
    • 25 Apr 2021 Results (n=1778) of updated analysis from CLEAR and CLARITY Trials; assessing the incremental burden of comorbid psoriatic arthritis on the clinical efficacy and safety of secukinumab vs ustekinumab among patients with moderate to severe plaque psoriasis, presented at the American Academy of Dermatology Virtual Meeting Experience 2021

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top